Monitoring of early response to neoadjuvant chemotherapy in breast cancer with 1H MR spectroscopy: Comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography

Journal of Magnetic Resonance Imaging

Volumn 28, Issue 2, 2008, Pages 420-427

  Tozaki, Mitsuhiro ^a   Sakamoto, Masaaki ^a   Oyama, Yu ^a   O'uchi, Toshihiro ^a   Kawano, Naoko ^a   Suzuki, Takako ^a   Yamashiro, Norie ^a   Ozaki, Shinji ^a   Sakamoto, Naomi ^a   Higa, Kuniki ^a   Abe, Satoko ^a   Ogawa, Tomoko ^a   Fukuma, Eisuke ^a  

^a KAMEDA MEDICAL CENTER   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; PET; Proton MRS; Therapeutic response

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GADOLINIUM PENTETATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; INTERMETHOD COMPARISON; LIVER DYSFUNCTION; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; ALGORITHMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHOLINE; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; NEOADJUVANT THERAPY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 49049121398     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21454     Document Type: Article

References (40)

1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-2685.
3. Goldhirsch A, Click JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817-3827.
4. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
5. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant chemotherapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-3417.
6. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 2001;13:868-875.
7. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179:1193-1199.
8. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184:868-877.
9. Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity, Br J Radiol 1997;70:452-458.
10. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76.
11. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998;209:269-275.
12. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998;8:1191-1197.
13. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999;10:159-164.
14. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001;68:45-54.
15. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopyinitial results. Radiology 2001;220:40-46.
16. Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001;84:1016-1022.
17. Tse GM, Cheung HS, Pang LM, et al. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR Am J Roentgenol 2003;181:1267-1272.
18. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004;232:585-591.
19. Bartella L, Morris EA, Dershaw DD, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006;239:686-692.
20. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-4276.
21. Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 2006;24:325-332.
22. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 2004;233:424-431.
23. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
24. Crippa F, Agrest R, Seregni E, et al. Prospective evaluation of [18F]FDG positron emission tomography (PET) in the presurgical staging of the axilla in breast cancer: comparison between PET and postoperative pathology. J Nucl Med 1998;39:4-8.
25. Dose Schwarz J, Bader M, Jenlcke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-1150.
26. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24:5366-5372.
27. World Health Organization Classification of Tumors. Pathology and genetics of tumours of the breast and female genital organs. Lyon, France: IARC; 2003:11-12.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst 2000;92:205-216.
29. American College of Radiology. Breast imaging reporting and data system (BI-RADS), 4th edition. Reston, VA: American College of Radiology; 2003:79-89.
30. Bottomley PA. On restoring motion-induced signal loss in single-voxel magnetic resonance spectra. Ann NY Acad Sci 1987;508:333-348.
31. Haase A, Frahm J, Hänicke W, Matthaei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985;30:341-344.
32. Mescher M, Tannus A, Johnson MO, Garwood M. Solvent suppression using selective echo dephasing. J Magn Reson A 1996;123,226-229.
33. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-321.
34. Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267-274.
35. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 1988;169:49-54.
36. Tozaki M, Kobayashi T, Uno S, et al. Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern. AJR Am J Roentgenol 2006;186:431-439.
37. Crippa F, Seregni E, Agresti R, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-1434.
38. Stanwell P, Gluch L, Clark D, et al. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol 2005;15:1037-1043.
39. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with IH MR spectroscopy. Magn Reson Med 2003;50:1134-1143.
40. Bakken IJ, Gribbestad IS, Singstad TE, Kvistad KA. External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5 Tesla, Magn Reson Med 2001;46:189-192.